NYSE:RDY - Dr. Reddy's Laboratories Stock Price, Price Target & More

$31.74 -0.01 (-0.03 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$31.74
Today's Range$31.39 - $31.88
52-Week Range$29.83 - $42.97
Volume293,771 shs
Average Volume296,303 shs
Market Capitalization$5.37 billion
P/E Ratio28.59
Dividend Yield0.91%
Beta0.28

About Dr. Reddy's Laboratories (NYSE:RDY)

Dr. ReddyDr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2017, this segment had 16 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies; and strategic collaboration with Amgen Inc. for the commercialization of oncology and osteoporosis medicines. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:RDY
CUSIPN/A
Phone91-40-4900-2900

Debt

Debt-to-Equity Ratio0.20%
Current Ratio1.50%
Quick Ratio1.13%

Price-To-Earnings

Trailing P/E Ratio28.59
Forward P/E Ratio29.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.17 billion
Price / Sales2.42
Cash Flow$2.1302 per share
Price / Cash14.90
Book Value$11.55 per share
Price / Book2.75

Profitability

EPS (Most Recent Fiscal Year)$1.11
Net Income$186 million
Net Margins6.95%
Return on Equity8.79%
Return on Assets4.89%

Miscellaneous

EmployeesN/A
Outstanding Shares165,830,000

Dr. Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced a None dividend on Friday, August 4th. Investors of record on Monday, July 17th will be given a dividend of $0.294 per share on Thursday, August 10th. The ex-dividend date of this dividend is Thursday, July 13th. View Dr. Reddy's Laboratories' Dividend History.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories (NYSE:RDY) announced its quarterly earnings results on Tuesday, July, 26th. The company reported $0.00 earnings per share for the quarter. The company earned $479 million during the quarter, compared to analysts' expectations of $557 million. Dr. Reddy's Laboratories had a net margin of 6.95% and a return on equity of 8.79%. View Dr. Reddy's Laboratories' Earnings History.

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Friday, May, 11th 2018. View Earnings Estimates for Dr. Reddy's Laboratories.

What price target have analysts set for RDY?

4 analysts have issued 1 year price targets for Dr. Reddy's Laboratories' stock. Their forecasts range from $30.51 to $30.51. On average, they expect Dr. Reddy's Laboratories' stock price to reach $30.51 in the next year. View Analyst Ratings for Dr. Reddy's Laboratories.

Who are some of Dr. Reddy's Laboratories' key competitors?

Who are Dr. Reddy's Laboratories' key executives?

Dr. Reddy's Laboratories' management team includes the folowing people:
  • Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.), Co-Chairman, MD & CEO (Age 58)
  • Mr. Kallam Satish Reddy B.Tech., M.S., Chairman (Age 51)
  • Mr. Saumen Chakraborty B.Sc. (H), MBA-IIM, Pres, CFO and Global Head of Information Technology & Bus. Process Excellence (Age 57)
  • Dr. Sripada Chandrasekhar Mba., Ph.D., Pres & Global Head of HR (Age 61)
  • Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D., Sr. VP & Bus. Head of PSAI Commercial Organization (Age 55)

Has Dr. Reddy's Laboratories been receiving favorable news coverage?

News coverage about RDY stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dr. Reddy's Laboratories earned a media sentiment score of 0.04 on Accern's scale. They also gave news stories about the company an impact score of 43.59 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $31.74.

How big of a company is Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories has a market capitalization of $5.37 billion and generates $2.17 billion in revenue each year. The company earns $186 million in net income (profit) each year or $1.11 on an earnings per share basis.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr. Reddy's Laboratories (RDY)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about Dr. Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dr. Reddy's Laboratories (NYSE:RDY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Dr. Reddy's Laboratories in the last 12 months. Their average twelve-month price target is $30.51, suggesting that the stock has a possible downside of 3.88%. The high price target for RDY is $30.51 and the low price target for RDY is $30.51. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.252.252.25
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.51$30.51$30.51$31.62
Price Target Upside: 3.88% downside16.11% downside16.11% downside11.38% downside

Dr. Reddy's Laboratories (NYSE:RDY) Consensus Price Target History

Price Target History for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE:RDY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017Jefferies GroupLower Price TargetUnderperform$31.62 -> $30.51N/AView Rating Details
9/21/2017Morgan StanleyUpgradeEqual Weight -> OverweightLowView Rating Details
8/31/2017CLSAUpgradeUnderperform -> OutperformHighView Rating Details
5/15/2017Deutsche BankUpgradeSell -> HoldHighView Rating Details
7/26/2016Credit Suisse GroupDowngradeNeutral -> UnderperformN/AView Rating Details
5/2/2016Goldman SachsInitiated CoverageNeutralN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Dr. Reddy's Laboratories (NYSE:RDY) Earnings History and Estimates Chart

Earnings by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE:RDY) Earnings Estimates

Current Year EPS Consensus Estimate: $1.07 EPS
Next Year EPS Consensus Estimate: $1.73 EPS

Dr. Reddy's Laboratories (NYSE RDY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2018        
1/25/2018Q3 2018$0.41$596.00 millionViewN/AView Earnings Details
10/31/2017Q2 2018$0.26$543.00 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.06$513.00 millionViewN/AView Earnings Details
5/12/2017Q4 2017$0.29$548.00 millionViewN/AView Earnings Details
2/4/2017Q3 2017$0.42$546.00 millionViewN/AView Earnings Details
10/25/2016Q2 2017$0.27$539.00 millionViewN/AView Earnings Details
7/26/2016Q117$0.0010$557.00 million$479.00 millionViewListenView Earnings Details
5/12/2016Q416$0.07$2.41 billion$567.00 billionViewListenView Earnings Details
2/9/2016Q316$0.51$2.48 million$599.00 millionViewN/AView Earnings Details
10/29/2015Q116$0.6460$2.54 billion$609.00 millionViewListenView Earnings Details
7/30/2015Q1 2016$0.58$611.03 million$591.00 millionViewN/AView Earnings Details
5/12/2015Q415$0.49$559.00 million$621.00 millionViewListenView Earnings Details
1/29/2015Q315$0.53$561.00 million$610.00 millionViewN/AView Earnings Details
10/29/2014Q2 2015$0.54$579.00 millionViewN/AView Earnings Details
7/30/2014Q115$0.54$474.00 million$486.00 millionViewN/AView Earnings Details
5/13/2014Q414$0.52$0.47$557.00 million$580.00 millionViewN/AView Earnings Details
2/11/2014Q314$0.45$0.59$558.20 million$571.00 millionViewN/AView Earnings Details
10/31/2013Q214$0.46$0.65$561.00 million$537.00 millionViewN/AView Earnings Details
7/30/2013Q413$0.43$0.40$551.40 million$478.00 millionViewN/AView Earnings Details
5/14/2013$0.60$635.50 million$613.00 millionViewN/AView Earnings Details
2/14/2013Q313$0.40$505.00 million$522.00 millionViewN/AView Earnings Details
10/30/2012Q2 2013$0.58ViewN/AView Earnings Details
7/19/2012Q1 2013$0.37ViewN/AView Earnings Details
5/11/2012Q4 2012$0.48ViewN/AView Earnings Details
2/3/2012Q3 2012$0.60ViewN/AView Earnings Details
10/25/2011Q2 2012$0.40ViewN/AView Earnings Details
7/20/2011Q1 2012$0.33ViewN/AView Earnings Details
5/13/2011Q4 2011$0.37ViewN/AView Earnings Details
1/25/2011Q3 2011$0.40ViewN/AView Earnings Details
10/23/2010Q2 2011$0.40ViewN/AView Earnings Details
7/22/2010Q1 2011$0.30ViewN/AView Earnings Details
5/6/2010Q4 2010$0.23ViewN/AView Earnings Details
1/20/2010Q3 2010$0.37$0.29ViewN/AView Earnings Details
10/23/2009Q2 2010$0.20$0.30ViewN/AView Earnings Details
7/21/2009Q1 2010$0.30ViewN/AView Earnings Details
5/18/2009Q4 2009$0.33$0.48ViewN/AView Earnings Details
1/20/2009Q3 2009$0.20ViewN/AView Earnings Details
10/23/2008Q2 2009$0.20ViewN/AView Earnings Details
7/21/2008Q1 2009$0.19ViewN/AView Earnings Details
5/20/2008Q4 2008$0.15ViewN/AView Earnings Details
1/25/2008Q3 2008$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dr. Reddy's Laboratories (NYSE:RDY) Dividend Information

Dr. Reddy's Laboratories pays an annual dividend of $0.29 per share, with a dividend yield of 0.91%. RDY's most recent none dividend payment was Thursday, August 10. Dr. Reddy's Laboratories pays out 26.13% of its earnings out as a dividend.
Most Recent Dividend:8/10/2017
Annual Dividend:$0.29
Dividend Yield:0.91%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:26.13% (Trailing 12 Months of Earnings)
27.10% (Based on This Year's Estimates)
16.76% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE:RDY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2017None$0.29407/13/20177/17/20178/10/2017
6/6/2017$0.297/13/20177/17/20177/17/2017
6/6/2016Annual$0.27707/14/20167/18/20167/18/2016
(Data available from 1/1/2013 forward)

Insider Trades

Dr. Reddy's Laboratories (NYSE RDY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 13.13%
Insider Trading History for Dr. Reddy`s Laboratories (NYSE:RDY)
Institutional Ownership by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Dr. Reddy's Laboratories (NYSE RDY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Dr. Reddy's Laboratories (NYSE RDY) News Headlines

Source:
DateHeadline
BRIEF-Dr.Reddys Labs Gets EIR From USFDA For API Mirfield Plant, UKBRIEF-Dr.Reddy's Labs Gets EIR From USFDA For API Mirfield Plant, UK
www.reuters.com - April 25 at 4:50 PM
Where Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Stands In Terms Of Earnings Growth Against Its IndustryWhere Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - April 23 at 8:55 AM
Dr. Reddys Laboratories (RDY) Receives Consensus Rating of "Hold" from AnalystsDr. Reddy's Laboratories (RDY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 16 at 1:35 AM
Dr. Reddys Laboratories (RDY) Lowered to "Sell" at BidaskClubDr. Reddy's Laboratories (RDY) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM
Dr. Reddys Laboratories (RDY) Stock Rating Lowered by BidaskClubDr. Reddy's Laboratories (RDY) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 12 at 5:45 PM
Dr. Reddys Laboratories (RDY) Lifted to "Hold" at ValuEngineDr. Reddy's Laboratories (RDY) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 12:31 AM
Dr. Reddys Laboratories (RDY) Upgraded at Zacks Investment ResearchDr. Reddy's Laboratories (RDY) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 2 at 12:58 PM
Dr. Reddys Laboratories (RDY) Price Target Cut to $30.51 by Analysts at Jefferies GroupDr. Reddy's Laboratories (RDY) Price Target Cut to $30.51 by Analysts at Jefferies Group
www.americanbankingnews.com - April 2 at 11:16 AM
Dr. Reddys Lab and Promius Pharma files NDA for its migraine candidateDr. Reddy's Lab and Promius Pharma files NDA for its migraine candidate
seekingalpha.com - April 2 at 9:39 AM
Dr. Reddys Laboratories (RDY) Announce Filing of NDA for Migraine CandidateDr. Reddy's Laboratories (RDY) Announce Filing of NDA for Migraine Candidate
www.streetinsider.com - April 2 at 9:39 AM
Dr. Reddys Lab announces senior leadership changesDr. Reddy's Lab announces senior leadership changes
seekingalpha.com - March 29 at 9:29 AM
Asian ADRs Move Sharply Lower in Thursday Trading - NasdaqAsian ADRs Move Sharply Lower in Thursday Trading - Nasdaq
www.nasdaq.com - March 22 at 4:46 PM
Dr. Reddys Laboratories (RDY) Given Average Rating of "Hold" by BrokeragesDr. Reddy's Laboratories (RDY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 22 at 1:52 AM
Asian ADRs Move Sharply Higher in Tuesday Trading - NasdaqAsian ADRs Move Sharply Higher in Tuesday Trading - Nasdaq
www.nasdaq.com - March 20 at 4:35 PM
Blog Exposure - Dr. Reddy’s Launches its Levocetirizine Dihydrochloride Tablets in the US MarketBlog Exposure - Dr. Reddy’s Launches its Levocetirizine Dihydrochloride Tablets in the US Market
finance.yahoo.com - March 20 at 9:23 AM
Dr. Reddys Laboratories launches Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. marketDr. Reddy's Laboratories launches Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. market
seekingalpha.com - March 17 at 9:21 AM
New Vernon Capital Holdings II LLC Invests $2.53 Million in Dr.Reddy's Laboratories Ltd (RDY) StockNew Vernon Capital Holdings II LLC Invests $2.53 Million in Dr.Reddy's Laboratories Ltd (RDY) Stock
www.americanbankingnews.com - March 6 at 9:05 AM
Portland Hill Asset Management Ltd Has $2.10 Million Holdings in Dr.Reddy's Laboratories Ltd (RDY)Portland Hill Asset Management Ltd Has $2.10 Million Holdings in Dr.Reddy's Laboratories Ltd (RDY)
www.americanbankingnews.com - March 6 at 8:48 AM
Innoviva (INVA) vs. Dr.Reddy's Laboratories (RDY) Head to Head ComparisonInnoviva (INVA) vs. Dr.Reddy's Laboratories (RDY) Head to Head Comparison
www.americanbankingnews.com - March 5 at 5:08 PM
Dalton Investments LLC Grows Position in Dr.Reddy's Laboratories Ltd (RDY)Dalton Investments LLC Grows Position in Dr.Reddy's Laboratories Ltd (RDY)
www.americanbankingnews.com - March 4 at 5:39 AM
Dr.Reddy's Laboratories Ltd (RDY) Stake Decreased by First Trust Advisors LPDr.Reddy's Laboratories Ltd (RDY) Stake Decreased by First Trust Advisors LP
www.americanbankingnews.com - March 2 at 8:18 AM
NINE MASTS CAPITAL Ltd Purchases 33,400 Shares of Dr.Reddy's Laboratories Ltd (RDY)NINE MASTS CAPITAL Ltd Purchases 33,400 Shares of Dr.Reddy's Laboratories Ltd (RDY)
www.americanbankingnews.com - February 27 at 2:30 PM
Dr.Reddy's Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from AnalystsDr.Reddy's Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 25 at 1:42 AM
Financial Contrast: Amicus Therapeutics (FOLD) & Dr.Reddy's Laboratories (RDY)Financial Contrast: Amicus Therapeutics (FOLD) & Dr.Reddy's Laboratories (RDY)
www.americanbankingnews.com - February 12 at 7:22 PM
Does Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) PE Ratio Warrant A Sell?Does Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) PE Ratio Warrant A Sell?
finance.yahoo.com - February 9 at 9:24 AM
Indivior sues rivals over Suboxone patents in U.S.Indivior sues rivals over Suboxone patents in U.S.
www.marketwatch.com - February 8 at 8:44 AM
Dr.Reddy's Laboratories (RDY) Cut to "Sell" at ValuEngineDr.Reddy's Laboratories (RDY) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 3:54 PM
Dr. Reddys Laboratories Announces the Launch of Tetrabenazine ... - Business Wire (press release)Dr. Reddy's Laboratories Announces the Launch of Tetrabenazine ... - Business Wire (press release)
www.businesswire.com - February 2 at 9:21 AM
Will Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Continue To Underperform Its Industry?Will Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Continue To Underperform Its Industry?
finance.yahoo.com - February 1 at 9:25 AM
Dr.Reddy's Laboratories Ltd (RDY) Receives Consensus Rating of "Hold" from AnalystsDr.Reddy's Laboratories Ltd (RDY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 31 at 1:52 AM
FY2018 EPS Estimates for Dr.Reddy's Laboratories Ltd Reduced by Jefferies Group (RDY)FY2018 EPS Estimates for Dr.Reddy's Laboratories Ltd Reduced by Jefferies Group (RDY)
www.americanbankingnews.com - January 30 at 10:54 AM
Doctor Reddys posts 3Q profitDoctor Reddy's posts 3Q profit
finance.yahoo.com - January 25 at 9:21 AM
Dr. Reddy’s Q3 and 9M FY18 Financial ResultsDr. Reddy’s Q3 and 9M FY18 Financial Results
finance.yahoo.com - January 25 at 9:21 AM
Dr.Reddy's Laboratories (RDY) to Release Quarterly Earnings on ThursdayDr.Reddy's Laboratories (RDY) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - January 18 at 2:50 AM
Dr. Reddys to release Q3 FY18 results on January 25, 2018Dr. Reddy's to release Q3 FY18 results on January 25, 2018
finance.yahoo.com - January 16 at 8:33 AM
Dr. Reddys Laboratories Limited to Present at the 36th Annual JP Morgan Healthcare Conference - Business Wire (press release)Dr. Reddy's Laboratories Limited to Present at the 36th Annual JP Morgan Healthcare Conference - Business Wire (press release)
www.businesswire.com - January 6 at 3:26 PM
Dr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from AnalystsDr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 6 at 1:26 AM
Asian ADRs Move Higher in Tuesday Trading - Nasdaq.com - NasdaqAsian ADRs Move Higher in Tuesday Trading - Nasdaq.com - Nasdaq
www.nasdaq.com - January 2 at 3:32 PM
Dr.Reddy's Laboratories (RDY) Upgraded to Hold at Zacks Investment ResearchDr.Reddy's Laboratories (RDY) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Bullish Two Hundred Day Moving Average Cross - RDY - Nasdaq.com - NasdaqBullish Two Hundred Day Moving Average Cross - RDY - Nasdaq.com - Nasdaq
www.nasdaq.com - December 30 at 3:26 PM
Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?
finance.yahoo.com - December 30 at 8:40 AM
ETFs with exposure to Dr. Reddy’s Laboratories Ltd. : December 27, 2017ETFs with exposure to Dr. Reddy’s Laboratories Ltd. : December 27, 2017
finance.yahoo.com - December 27 at 3:17 PM
Form 6-K DR REDDYS LABORATORIES For: Dec 26Form 6-K DR REDDYS LABORATORIES For: Dec 26
www.streetinsider.com - December 26 at 11:05 PM
Asian ADRs Move Lower in Tuesday Trading - NasdaqAsian ADRs Move Lower in Tuesday Trading - Nasdaq
www.nasdaq.com - December 26 at 6:02 PM
Health Care Sector Update for 12/26/2017: PTLA, ALXN, ABBV, ZSAN, RDY, NVS - NasdaqHealth Care Sector Update for 12/26/2017: PTLA, ALXN, ABBV, ZSAN, RDY, NVS - Nasdaq
www.nasdaq.com - December 26 at 6:02 PM
Dr. Reddys Labs Launches Melphalan Hydrochloride For Injection In US - NasdaqDr. Reddy's Labs Launches Melphalan Hydrochloride For Injection In US - Nasdaq
www.nasdaq.com - December 26 at 6:02 PM
Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 1:01 PM
How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?
finance.yahoo.com - December 21 at 8:09 AM
Dr. Reddys announces it has reached a settlement with the US Government regarding companys compliance with the ... - Business Wire (press release)Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the ... - Business Wire (press release)
www.businesswire.com - December 19 at 8:33 AM
Dr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety ActDr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety Act
finance.yahoo.com - December 19 at 8:32 AM

SEC Filings

Dr. Reddy's Laboratories (NYSE:RDY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dr. Reddy's Laboratories (NYSE:RDY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dr. Reddy's Laboratories (NYSE RDY) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.